EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Risk factors assessment and therapeutic drug management of sars covid-19 virus

Navya Anusha N, Krishna Sapavath, Bhargava Narendra J

UPI Journal of Pharmaceutical, Medical and Health Sciences · 2020

DOI: 10.37022/jpmhs.v3i4.34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift UPI Journal of Pharmaceutical, Medical and Health Sciences, 2020. Verfasst von Navya Anusha N und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe acute respiratory syndrome corona virus (COV)-2(SARS-COV-2) previously called 2019 novel cov emerged from china. This virus causes cov disease-19(COVID-19), favipiravir (1000mg) is an oral anti-viral that inhibits RNA polymerase that is a pproved in Russia during phase 2/3 clinical trials for the treatment of covid. Ivermectin an antiparasitic drug showed an in-vitro reduction of viral RNA in vero-hslam cells 2hr post-infection with SARS-COV-2.corticosteroids include dexamethasone (6mg), Methyl Prednisolone (80mg) can induce harm through immunosuppressant effects during treatment of infection and a study in the Netherlands showed a 5-day course of high dose corticosteroids accelerated respiratory recovery lowered hospital mortality rates and reduced the likelihood of mechanical ventilation in patients with severe COVID-19 associated cytokine storm syndrome. Use of convalescent PLASMA after a multicentre study conducted by Mayo clinic indicates transfusion of ABO-compatible human covid-19 is safe and effective in hospitalized adults. NAK and JAK inhibitors may mitigate systemic and alveolar inflammation in patience with covid-19 pneumonia by inhibiting essential cytokine signaling drugs include baricitinib (4mg), fedratinib (100mg), ruxolitinib (5mg). Statins decrease the inflammatory processes of atherosclerosis. Vitamins and mineral supplements have been promoted for the treatment of respiratory viral infections. Hydroxychloroquine(400mg) and chloroquine (600mg) are widely used anti-malarial drugs that elicit immunomodulatory effects based on PBPK models recommended loading dose of HCQ is 400mg (BID) followed by 200mg (BID) for four days. In a randomized controlled, open-label trial of hospitalized adults with conformed SARSCOV-2, recruited patients had 02 saturation of 94% less than ambient air or pao2 of less than 300mmhg were randomized to receive Lopinavir/Ritonavir 400mg/100mg for 14 days, Adjunctive nutritional therapies also recommended.

Zitieren

APA

N, N. A., Sapavath, K., & J, B. N. (2020). Risk factors assessment and therapeutic drug management of sars covid-19 virus. UPI Journal of Pharmaceutical, Medical and Health Sciences. https://doi.org/10.37022/jpmhs.v3i4.34

Vancouver

N NA, Sapavath K, J BN. Risk factors assessment and therapeutic drug management of sars covid-19 virus. UPI Journal of Pharmaceutical, Medical and Health Sciences. 2020. doi:10.37022/jpmhs.v3i4.34

BibTeX
@article{N2020,
  author = {N, Navya Anusha and Sapavath, Krishna and J, Bhargava Narendra},
  title = {Risk factors assessment and therapeutic drug management of sars covid-19 virus},
  journal = {UPI Journal of Pharmaceutical, Medical and Health Sciences},
  year = {2020},
  doi = {10.37022/jpmhs.v3i4.34}
}
Kostenlos starten →